Cargando…
Concurrent targeting of BMI1 and CDK4/6 abrogates tumor growth in vitro and in vivo
Despite recent advances in cancer management and therapy, resistance to cytotoxic medications remains a major clinical challenge; hence, combination-based anti-cancer treatment regimens are currently gaining momentum. PTC-209 reduced BMI1 protein expression, while palbociclib inhibited CDK4, Rb, and...
| Autores principales: | , , , , , , , , |
|---|---|
| Formato: | Online Artículo Texto |
| Lenguaje: | English |
| Publicado: |
Nature Publishing Group UK
2019
|
| Materias: | |
| Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6757061/ https://www.ncbi.nlm.nih.gov/pubmed/31548560 http://dx.doi.org/10.1038/s41598-019-50140-0 |